WO2006131749A3 - Scaffold - Google Patents

Scaffold Download PDF

Info

Publication number
WO2006131749A3
WO2006131749A3 PCT/GB2006/002115 GB2006002115W WO2006131749A3 WO 2006131749 A3 WO2006131749 A3 WO 2006131749A3 GB 2006002115 W GB2006002115 W GB 2006002115W WO 2006131749 A3 WO2006131749 A3 WO 2006131749A3
Authority
WO
WIPO (PCT)
Prior art keywords
stefin
scaffold
mutations
relates
leu73
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/002115
Other languages
French (fr)
Other versions
WO2006131749A2 (en
Inventor
Robbie Woodman
Johannes Tsung-Han Yeh
Sophie Laurenson
Ferrigno Paul Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511873A external-priority patent/GB0511873D0/en
Priority claimed from GB0608836A external-priority patent/GB0608836D0/en
Priority to AT06744166T priority Critical patent/ATE477272T1/en
Priority to US11/917,057 priority patent/US8063019B2/en
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to CA2610976A priority patent/CA2610976C/en
Priority to DK06744166.7T priority patent/DK1904529T3/en
Priority to DE602006016133T priority patent/DE602006016133D1/en
Priority to JP2008515292A priority patent/JP4989638B2/en
Priority to AU2006256530A priority patent/AU2006256530B2/en
Priority to EP06744166A priority patent/EP1904529B1/en
Publication of WO2006131749A2 publication Critical patent/WO2006131749A2/en
Publication of WO2006131749A3 publication Critical patent/WO2006131749A3/en
Anticipated expiration legal-status Critical
Priority to US13/243,318 priority patent/US8481491B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A sequence to improve it as a scaffold; preferably the Stefin A comprises a heterologous peptide insertion at the Leu 73 site. Furthermore, preferably the scaffold protein comprises a V48D mutation; preferably the scaffold protein comprises a G4W mutation. Preferably the scaffold comprises Leu73, V48D and G4W mutations. The invention also relates to the scaffold proteins themselves, in particular a stefin A polypeptide having the Leu73, V48D and G4W mutations, such as shown as SEQ ID NO: 1. The invention also relates to a method for identifying binding proteins and to peptide A (RLNKPLPSLPV) and its use in treating yeast infections.
PCT/GB2006/002115 2005-06-10 2006-06-08 Scaffold Ceased WO2006131749A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2006256530A AU2006256530B2 (en) 2005-06-10 2006-06-08 Scaffold
US11/917,057 US8063019B2 (en) 2005-06-10 2006-06-08 Scaffold polypeptides for heterologous peptide display
EP06744166A EP1904529B1 (en) 2005-06-10 2006-06-08 Use of stefin a as a scaffold protein
AT06744166T ATE477272T1 (en) 2005-06-10 2006-06-08 USE OF STEFIN A AS A SUPPORTING PROTEIN
CA2610976A CA2610976C (en) 2005-06-10 2006-06-08 Use of stefin a as a scaffold protein
DK06744166.7T DK1904529T3 (en) 2005-06-10 2006-06-08 Use of Stefin A as a Scaffold Protein
DE602006016133T DE602006016133D1 (en) 2005-06-10 2006-06-08 USE OF STEFIN A AS A FRUIT PROTEIN
JP2008515292A JP4989638B2 (en) 2005-06-10 2006-06-08 scaffold
US13/243,318 US8481491B2 (en) 2005-06-10 2011-09-23 Scaffold polypeptides for heterologous peptide display

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0511873A GB0511873D0 (en) 2005-06-10 2005-06-10 Scaffold
GB0511873.2 2005-06-10
GB0608836.3 2006-05-04
GB0608836A GB0608836D0 (en) 2006-05-04 2006-05-04 Scaffold

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/917,057 A-371-Of-International US8063019B2 (en) 2005-06-10 2006-06-08 Scaffold polypeptides for heterologous peptide display
US13/243,318 Continuation US8481491B2 (en) 2005-06-10 2011-09-23 Scaffold polypeptides for heterologous peptide display

Publications (2)

Publication Number Publication Date
WO2006131749A2 WO2006131749A2 (en) 2006-12-14
WO2006131749A3 true WO2006131749A3 (en) 2007-05-18

Family

ID=37314237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002115 Ceased WO2006131749A2 (en) 2005-06-10 2006-06-08 Scaffold

Country Status (9)

Country Link
US (2) US8063019B2 (en)
EP (1) EP1904529B1 (en)
JP (1) JP4989638B2 (en)
AT (1) ATE477272T1 (en)
AU (1) AU2006256530B2 (en)
CA (1) CA2610976C (en)
DE (1) DE602006016133D1 (en)
DK (1) DK1904529T3 (en)
WO (1) WO2006131749A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610976C (en) * 2005-06-10 2020-11-24 Robbie Woodman Use of stefin a as a scaffold protein
GB0807065D0 (en) 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
GB201302597D0 (en) * 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US10851410B2 (en) 2017-01-04 2020-12-01 Mgi Tech Co., Ltd. Nucleic acid sequencing using affinity reagents
BR112019019630A2 (en) 2017-05-19 2020-04-14 Philip Morris Products S.A. diagnostic test to distinguish a subject's smoking status
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US20230097573A1 (en) * 2019-10-16 2023-03-30 Lg Chem, Ltd. Neonatal fc receptor binding affimers
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
US20230366023A1 (en) 2020-10-09 2023-11-16 Bgi Shenzhen Co., Ltd. Methods and compositions for bioluminescence-based sequencing
WO2023153876A1 (en) * 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Stefin a protein variants specifically binding to cd40l, and uses thereof
EP4499664A4 (en) * 2022-03-24 2026-04-08 Agency Science Tech & Res Production of peptides using the evolution of peptides epitoplinks
US20260022343A1 (en) * 2022-12-29 2026-01-22 Affyxell Therapeutics Co., Ltd. Genetically modified cells comprising a nucleic acid encoding a cd40l binding agent and uses thereof
GB202403780D0 (en) 2024-03-15 2024-05-01 Avacta Life Sciences Ltd Polypeptides and methods for detecting and quantifying small molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005406A1 (en) * 1998-07-20 2000-02-03 M & E Biotech A/S Novel methods for the identification of ligand and target biomolecules
WO2005046709A2 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Tgf - beta binding and supported peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715747B2 (en) * 1994-11-21 2000-02-10 University Of Leeds, The Modified proteinase inhibitors
CA2610976C (en) * 2005-06-10 2020-11-24 Robbie Woodman Use of stefin a as a scaffold protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005406A1 (en) * 1998-07-20 2000-02-03 M & E Biotech A/S Novel methods for the identification of ligand and target biomolecules
WO2005046709A2 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Tgf - beta binding and supported peptides

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARANA DAVID M ET AL: "The Pbs2 MAP kinase kinase is essential for the oxidative-stress response in the fungal pathogen Candida albicans", MICROBIOLOGY (READING), vol. 151, April 2005 (2005-04-01), pages 1033 - 1049, XP002419826, ISSN: 1350-0872 *
BORGHOUTS C ET AL: "PEPTIDE APTAMERS: RECENT DEVELOPMENTS FOR CANCER THERAPY", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 5, no. 6, 1 June 2005 (2005-06-01), pages 783 - 797, XP009055849, ISSN: 1471-2598 *
DATABASE EMBL [online] 2 April 1988 (1988-04-02), "Human radiated keratinocyte mRNA for cysteine protease inhibitor", XP002409648, retrieved from EBI accession no. EM_PRO:X05978 Database accession no. X05978 *
LUPETTI ANTONELLA ET AL: "Antimicrobial peptides: therapeutic potential for the treatment of Candida infections.", EXPERT OPINION ON INVESTIGATIONAL DRUGS FEB 2002, vol. 11, no. 2, February 2002 (2002-02-01), pages 309 - 318, XP002419828, ISSN: 1354-3784 *
MARTIN J R ET AL: "The three-dimensional solution structure of human stefin A.", JOURNAL OF MOLECULAR BIOLOGY. 17 FEB 1995, vol. 246, no. 2, 17 February 1995 (1995-02-17), pages 331 - 343, XP002409646, ISSN: 0022-2836 *
WOODMAN ET AL: "Design and Validation of a Neutral Protein Scaffold for the Presentation of Peptide Aptamers", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 352, no. 5, 7 October 2005 (2005-10-07), pages 1118 - 1133, XP005074554, ISSN: 0022-2836 *
ZARRINPAR A ET AL: "Optimization of specificity in a cellular protein interaction network by negative selection", NATURE 11 DEC 2003 UNITED KINGDOM, vol. 426, no. 6967, 11 December 2003 (2003-12-11), pages 676 - 680, XP002409636, ISSN: 0028-0836 *
ZARRINPAR A ET AL: "Optimization of specificity in a cellular protein interaction network by negative selection. Supplementary figures S6-S8.", NATURE 11 DEC 2003 UNITED KINGDOM, vol. 426, no. 6967, 11 December 2003 (2003-12-11), pages 676 - 680, XP002409637, ISSN: 0028-0836, Retrieved from the Internet <URL:http://www.nature.com/nature/journal/v426/n6967/extref/nature02178-s4.jpg> [retrieved on 20061129] *
ZARRINPAR ALI ET AL: "Sho1 and Pbs2 act as coscaffolds linking components in the yeast high osmolarity MAP kinase pathway.", MOLECULAR CELL 18 JUN 2004, vol. 14, no. 6, 18 June 2004 (2004-06-18), pages 825 - 832, XP002419827, ISSN: 1097-2765 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses

Also Published As

Publication number Publication date
CA2610976C (en) 2020-11-24
CA2610976A1 (en) 2006-12-14
DE602006016133D1 (en) 2010-09-23
US8063019B2 (en) 2011-11-22
US20080207509A1 (en) 2008-08-28
EP1904529B1 (en) 2010-08-11
US8481491B2 (en) 2013-07-09
EP1904529A2 (en) 2008-04-02
WO2006131749A2 (en) 2006-12-14
US20120190819A1 (en) 2012-07-26
JP2008541776A (en) 2008-11-27
ATE477272T1 (en) 2010-08-15
JP4989638B2 (en) 2012-08-01
AU2006256530B2 (en) 2012-12-20
DK1904529T3 (en) 2010-11-15
AU2006256530A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2006131749A3 (en) Scaffold
EP2071028A3 (en) HLA-DR-binding antigen peptide derived from WT1
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2006033702A3 (en) Anti-cd154 antibodies
DE60035419D1 (en) ANTIGENIC PEPTIDES FROM NEISSERIA
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO2002016418A3 (en) An iap binding peptide or polypeptide and methods of using the same
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2005060350A3 (en) Diastereomeric peptides useful as inhibitors of membrane protein assembly
WO2002070665A3 (en) Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2002026947A3 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
EP2261332A3 (en) Libraries of recombinant chimeric proteins
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
ATE346091T1 (en) NEW DIAGNOSTIC REAGENT AND KIT FOR DETECTION OF RICKETSIOSIS
WO2004053117A3 (en) Serine protease
WO2007058267A8 (en) Novel protein and gene encoding the protein
WO2002016566A3 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002050286A3 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2001081413A3 (en) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002077166A3 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2003902414A0 (en) Flowering induction
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2007073845A8 (en) Polypeptide having esterase activity and recombinant esterase and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008515292

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2610976

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11917057

Country of ref document: US

Ref document number: 2006256530

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006744166

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006256530

Country of ref document: AU

Date of ref document: 20060608

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006256530

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06744166

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006744166

Country of ref document: EP